Business Context and Reporting Period
AirSculpt Technologies, Inc. (NASDAQ: AIRS) is a national provider of body contouring procedures operating 32 centers across 20 states, Canada, and the United Kingdom. The company utilizes a proprietary, minimally invasive method for fat removal and skin tightening. This summary covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $44.0 million | $83.4 million |
| Net Loss | $(0.6) million | $(3.4) million |
| Adjusted EBITDA | $5.8 million | $9.6 million |
| Operating Cash Flow | N/A | $5.9 million |
| Cash and Equivalents | $8.2 million | $8.2 million |
| Total Debt (Net) | $57.7 million | $57.7 million |
| Working Capital | $(9.4) million deficit | $(9.4) million deficit |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 13.7% year-over-year (YoY) for the quarter and 15.5% YoY for the six-month period. This was driven by a 14.1% decline in total cases performed (3,392 vs. 3,949) and a 22.0% decline in same-center cases.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses dropped significantly, down 33.9% for the quarter and 11.2% for the six months. This was due to reduced advertising spend ($3.4M reduction in Q2), lower severance costs, and decreased stock compensation expense.
- Profitability: The company narrowed its net loss significantly compared to the prior year, reporting a net loss of $0.6 million for the quarter compared to $3.2 million in the same period in 2024. Adjusted EBITDA margin was 13.3% for the quarter.
- Debt Repayment: The company utilized proceeds from a recent equity offering to make a $10.0 million principal payment on its term loan in June 2025.
Guidance, Outlook, and Risks
Strategic Initiatives: Management announced a plan to stabilize revenue growth by optimizing marketing investments, improving go-to-market strategies, enhancing customer experience, and expanding consumer financing. A cost reduction program targeting $3.0 million in annual overhead savings has been implemented, and new center openings have been paused.
Capital Markets: In June 2025, the company completed an underwritten public offering, raising approximately $13.8 million in net proceeds. It also maintains an At-The-Market (ATM) offering program with up to $50.0 million capacity.
Debt Covenants: The company amended its credit agreement in March 2025 to modify financial covenants, including leverage ratios and fixed charge coverage ratios. It must maintain minimum liquidity of $7.5 million as of May 31, 2025, and thereafter. Interest rates on outstanding loans increased effective July 1, 2025, based on leverage ratios.
Risks: Key risks include the impact of weight-loss drugs on the aesthetics market, competition, inability to stabilize same-center performance, and the potential for future equity dilution to raise capital. The company is also evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed into law on July 4, 2025, regarding changes to federal tax law.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to meet the new minimum liquidity covenant of $7.5 million and the revised leverage ratios under the amended credit agreement.
- Revenue Stabilization: Monitor upcoming quarters for signs of stabilization in same-center case volumes and revenue per case following the strategic pivot.
- Capital Structure: Assess the impact of the recent equity offering on shareholder dilution and the sustainability of the $57.7 million debt load given the current revenue trajectory.
- Cost Savings Realization: Confirm the realization of the targeted $3.0 million in annual overhead cost reductions.
- Regulatory Impact: Review future filings for the specific financial impact of the new "One Big Beautiful Bill Act" tax legislation.